Top
image credit: Adobe Stock

AstraZeneca’s Imjudo/Imfinzi combination approved by FDA for unresectable liver cancer

October 24, 2022

Via: PMLiVE
Category:

The dosing schedule of the combination has been referred to as the STRIDE (Single Tremelimumab Regular Interval Durvalumab) regimen, which includes a single dose of Imjudo 300mg added to Imfinzi 1500mg followed by Imfinzi every four weeks.

The approval is based on positive results from the global phase 3 HIMALAYA trial, a randomised, open-label, multicentre study in 1,324 patients with unresectable, advanced HCC who had not been treated with prior systemic therapy and were not eligible for locoregional therapy.

Read More on PMLiVE